| Cord Blood America CEO Interview Details the Value of New 'Afford-A-Cord' Program (PR Newswire) Cord Blood America, Inc. , said today that its co-founder and CEO, Matthew Schissler, reviewed the reasons for and significant details about its new "Afford-A-Cord" program in an interview with analyst Francis Gaskins. us.rd.yahoo.com |
Generex: Reverse Split Not Approved Thomas Barnard submits:Funding for the development companies that I have followed over the years always have their problems. While the product is being developed, which can take five or ten or fifteen years, the managers have the job of continuing to find funding for the development.Unfortunately for investors, this process usually sees stock prices in continual decline. Generex is no exception to this. Shares have been sold to new large investors in ever declining prices.Complete Story » seekingalpha.com |
Questcor Pharma: Acthar Approval Seems Likely Sheff Station submits:In the second week in May, the Peripheral and Central Nervous System Drugs Advisory Committee to the FDA held a panel meeting to discuss approval for using Questcor’s (QCOR) Acthar in the treatment of infantile spasms. The meeting went very well as the panel's purpose was to advise the FDA on their opinion of whether or not Acthar should be approved by the FDA for this condition. The vote by panel members was overwhelmingly in favor of an approval for Acthar. What this article will do is discuss the breakdown of the voting and give insight on what can be expected from the FDA on September 11th. Since the panel meeting, the original PDUFA date of June 11 was extended to September 11. The FDA is currently reviewing information regarding labeling, REMS and a potential post-approval commitment that they requested from Questcor. If Questcor obtains FDA approval to add IS to the Acthar label in September, then Questcor expects to launch Acthar, for the treatment of IS, during the Child Neurology Society Annual Meeting on October 4th. An approval of their drug would be the first time that they would be able to promote Acthar for the treatment in infantile spasms. With an approved indication, they can target public education efforts regarding the importance of early diagnosis and effective treatment of IS.Complete Story » seekingalpha.com |
Forest Labs Sees Large Call Selling optionMONSTER submits: By Chris McKhann Forest Laboratories (FRX) has climbed to a new two-year high, but the big trade so far today is someone selling the upside in the pharmaceutical company. Complete Story » seekingalpha.com |
HealthSeeker™ Explorando tu Salud, Paso a Paso - Video Nuevo juego de Facebook® Encara el Alarmante índice de Diabetes entre los Latinos feedproxy.google.com |